ArticleCase reports in medicine2019
Spontaneous Regression of Hepatocellular Carcinoma and Review of Reports in the Published English Literature.
Article in Case reports in medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- A Case of Transient Spontaneous Regression of Intrahepatic Cholangiocarcinoma Clinically Mimicking Inflammatory Pseudotumor: A Diagnostic Dilemma.Surgical case reports · 2026Article
- Article
- Complete regression of intrahepatic cholangiocarcinoma after right portal vein ligation. Case report.International journal of surgery case reports · 2024Article
- Spontaneous regression of hepatocellular carcinoma in a pure palliative care setting.Journal of general and family medicine · 2023Article
- Spontaneous regression of metastatic hepatocellular carcinoma following 3 weeks of lenvatinib.BMJ case reports · 2022Article
- Occurrence-regression-recurrence of hepatocellular carcinoma without any intervention: A case report.Frontiers in surgery · 2022Article
- Spontaneous Immune-Mediated Regression of Hepatocellular Carcinoma With High Tumor Mutational Burden.JCO precision oncology · 2021Article
- Complete Regression of Hepatocellular Carcinoma with Low Dose of Sorafenib.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpontaneous regression of hepatocellular carcinoma (HCC) is a rare event, although it has been described by numerous groups. The long-term fate of individuals experiencing an SR is not well described, and the underlying mechanism(s) of SR are unknown.
conclusionsThe case and a review of the literature illustrate that SR is often durable and associated with an excellent prognosis. Understanding the underlying mechanism of SR may point to novel therapeutic strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.